Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. | Journal of Immune Based Therapies and Vaccines BioMed Central Open Access Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers Curtis L Cooper1 Navneet K Ahluwalia2 Susan M Efler2 Jorg Vollmer3 Arthur M Krieg4 and Heather L Davis 2 Address division of Infectious Diseases University of Ottawa at The Ottawa Hospital and Ottawa Health Research Institute Ottawa Canada 2Coley Pharmaceutical Canada Ottawa Canada 3Coley Pharmaceutical GmbH Langenfeld Germany and 4Coley Pharmaceutical Group Wellesley MA USA Email Curtis L Cooper - ccooper@ Navneet K Ahluwalia - nahluwalia@ Susan M Efler - sefler@ Jorg Vollmer - jvollmer@ Arthur M Krieg - akrieg@ Heather L Davis - hdavis@ Corresponding author Published 9 June 2008 Received 15 March 2008 Journal of Immune Based Therapies and Vaccines 2008 6 3 doi l 476-85 18-6-3 Accepted 9 June 2008 This article is available from http content 6 1 3 2008 Cooper et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Chronic hepatitis C virus HCV infection results from weak or absent T cell responses. Pegylated-interferon-alpha IFN-a and ribavirin the standard of care for chronic HCV have numerous immune effects but are not potent T cell activators. A potent immune activator such as TLR9 agonist CpG oligodeoxynucleotide CpG may complement current treatment approaches. Methods Peripheral blood mononuclear cells PBMC obtained from HCV chronic carriers who failed previous treatment and from healthy donors were incubated in vitro with the three main CpG classes A B or C recombinant IFN-a-2b IntronA and or .
